Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration

BACKGROUND AND OBJECTIVE: To evaluate the change in drusen volume following treatment with eculizumab, a systemic inhibitor of complement component 5

Bibliographic Details
Published in:Ophthalmic surgery, lasers & imaging retina, Vol. 45, No. 1 (2014), p. 18-31
Main Author: Garcia Filho, Carlos Alexandre de Amorim
Other Involved Persons: Yehoshua, Zohar ; Gregori, Giovanni ; Nunes, Renata Portella ; Penha, Fernando M ; Moshfeghi, Andrew A ; Zhang, Kang ; Feuer, William ; Rosenfeld, Philip J
Format: electronic Article
Item Description:Date Completed 17.07.2014
Date Revised 22.10.2015
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
QR Code: Show QR Code